Full Text
PCN100 COST-EFFECTIVENESS OF GEFITINIB VERSUS DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN

Abstract

Authors

J Jacob M Henriksson D Brattstrm

Back to Volume 13, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×